Peregrine Asset Advisers’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-613
| Closed | -$305K | – | 177 |
|
|
2025
Q1 | $305K | Sell |
613
-82
| -12% | -$44.4K | 0.11% | 125 |
|
|
2024
Q4 | $362K | Sell |
695
-4,618
| -87% | -$2.54M | 0.13% | 110 |
|
|
2024
Q3 | $3.29M | Buy |
5,313
+4,742
| +830% | +$2.81M | 1.13% | 26 |
|
|
2024
Q2 | $316K | Hold |
571
| – | – | 0.12% | 124 |
|
|
2024
Q1 | $332K | Hold |
571
| – | – | 0.13% | 120 |
|
|
2023
Q4 | $303K | Sell |
571
-1,485
| -72% | -$719K | 0.15% | 120 |
|
|
2023
Q3 | $1.04M | Buy |
2,056
+677
| +49% | +$361K | 0.54% | 49 |
|
|
2023
Q2 | $719K | Hold |
1,379
| – | – | 0.55% | 40 |
|
|
2023
Q1 | $795K | Buy |
1,379
+200
| +17% | +$113K | 0.78% | 33 |
|
|
2022
Q4 | $649K | Sell |
1,179
-16
| -1% | -$8.48K | 0.69% | 27 |
|
|
2022
Q3 | $606K | Hold |
1,195
| – | – | 0.72% | 32 |
|
|
2022
Q2 | $649K | Buy |
+1,195
| New | +$658K | 0.47% | 39 |
|
|
2022
Q1 | – | Sell |
-9,950
| Closed | -$6.64M | – | 144 |
|
|
2021
Q4 | $6.64M | Buy |
9,950
+7,930
| +393% | +$4.95M | 2.7% | 10 |
|
|
2021
Q3 | $1.15M | Sell |
2,020
-376
| -16% | -$206K | 0.59% | 46 |
|
|
2021
Q2 | $1.21M | Buy |
2,396
+1,165
| +95% | +$550K | 0.55% | 51 |
|
|
2021
Q1 | $562K | Sell |
1,231
-179
| -13% | -$85.4K | 0.29% | 61 |
|
|
2020
Q4 | $657K | Buy |
1,410
+50
| +4% | +$23.4K | 0.31% | 67 |
|
|
2020
Q3 | $600K | Sell |
1,360
-117
| -8% | -$48.3K | 0.33% | 60 |
|
|
2020
Q2 | $535K | Sell |
1,477
-406
| -22% | -$136K | 0.3% | 52 |
|
|
2020
Q1 | $534K | Hold |
1,883
| – | – | 0.4% | 46 |
|
|
2019
Q4 | $612 | Hold |
1,883
| – | – | 0.14% | 60 |
|
|
2019
Q3 | $548K | Hold |
1,883
| – | – | 0.31% | 58 |
|
|
2019
Q2 | $553K | Sell |
1,883
-7
| -0.4% | -$1.93K | 0.29% | 69 |
|
|
2019
Q1 | $517K | Sell |
1,890
-16
| -0.8% | -$3.98K | 0.3% | 67 |
|
|
2018
Q4 | $427K | Sell |
1,906
-4,000
| -68% | -$938K | 0.56% | 41 |
|
|
2018
Q3 | $1.44M | Hold |
5,906
| – | – | 0.65% | 42 |
|
|
2018
Q2 | $1.22M | Hold |
5,906
| – | – | 0.63% | 44 |
|
|
2018
Q1 | $1.22M | Buy |
5,906
+2,000
| +51% | +$420K | 0.81% | 28 |
|
|
2017
Q4 | $741K | Buy |
3,906
+433
| +12% | +$83K | 0.37% | 47 |
|
|
2017
Q3 | $657K | Sell |
3,473
-592
| -15% | -$107K | 0.35% | 45 |
|
|
2017
Q2 | $709K | Buy |
+4,065
| New | +$683K | 0.45% | 39 |
|
|
2014
Q2 | – | Sell |
-1,717
| Closed | -$206K | – | 133 |
|
|
2014
Q1 | $206K | Buy |
+1,717
| New | +$204K | 0.16% | 109 |
|
|
2013
Q4 | – | Sell |
-8,218
| Closed | -$757K | – | 144 |
|
|
2013
Q3 | $757K | Sell |
8,218
-499
| -6% | -$45.1K | 0.73% | 31 |
|
|
2013
Q2 | $738K | Buy |
+8,717
| New | +$726K | 0.76% | 32 |
|
Other funds holding TMO
Peregrine Asset Advisers's TMO Position: Q2 2025 in Review
Peregrine Asset Advisers sold out of Thermo Fisher Scientific (TMO) in Q2 2025, closing a stake of 613 shares — an estimated $305K sold.
Peregrine Asset Advisers first reported a position in TMO in Q2 2013 and held it in 34 quarters. The position peaked at $6.64M in Q4 2021. 2,453 funds tracked by Wall St. Rank hold TMO as of Q2 2025.
- Peregrine Asset Advisers reported no remaining Thermo Fisher Scientific position as of Q2 2025 after selling out during the quarter.
- Peregrine Asset Advisers sold 613 Thermo Fisher Scientific shares in Q2 2025, an estimated $305K.
- Peregrine Asset Advisers first reported a position in Thermo Fisher Scientific in Q2 2013 and held it in 34 quarters.
- Peregrine Asset Advisers's Thermo Fisher Scientific position peaked at $6.64M in Q4 2021.
- 2,453 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2025.
Based on Peregrine Asset Advisers's 13F filing for Q2 2025, filed 5 Aug 2025.